产前应用沐舒坦预防早产儿呼吸窘迫综合征的临床研究

目的探讨产前应用沐舒坦对早产儿RDS的预防作用.方法孕27～34w面临早产或计划分娩的妇女80例,随机分为沐舒坦组和激素组各40例,观察早产儿RDS的发生率及严重程度,以及母婴感染等不良反应发生率.结果 (1)沐舒坦组早产儿RDS发生率为15.9 %,激素组为34.1 %,两组有显著性差异(P＜0.05);(2)沐舒坦组RDS的严重程度较激素组轻,有显著差异;(3)沐舒坦组早产儿获得性肺炎明显低于激素组(P＜0.05).结论产前预防性应用沐舒坦能减少早产儿RDS的发生率,与肾上腺皮质激素比较有减轻RDS严重程度,减少早产儿获得性肺炎的优越性.

Antenatal ambroxol usage in the prevention of premature infant respiratory distress syndrome(RDS)

Objective:To evaluate the effects of antenatal ambroxol usage in the prevention of premature infant respiratory distress syndrome(RDS).Methods:80 cases of pregnant women in 27-34 gestational weeks,who faced premature delivery or planned parturition,were randomly classified into groups of ambroxol and dexamethasone to observe the occurrence rate and severity of RDS in premature infants and the occurrence rate of infection of mother and infant.Results:The occurrence rate of premature infant RDS in ambroxol group is 15.9% while that in dexamethasone group is 34.1%.Two groups have a remarkable difference(P<0.05).The severity of RDS are lesser than that in dexamethasone group.Rate of acquired pneumonia of premature infant in ambroxol group is remarkable lower than that in dexamethasone group(P<0.05).Conclusions: Antenatal ambroxol usage can reduce the rate of premature infant RDS. Ambroxol is superior to dexamethasone in reducing rate of RDS and acquired pneumonia in premature infant.